Mirum Pharmaceuticals, Inc. filings document operating results, product-sales disclosures, clinical program updates and governance matters for a rare disease biopharmaceutical company. Its 8-K reports furnish earnings releases, preliminary sales information, Regulation FD investor materials and other event disclosures tied to LIVMARLI, CHOLBAM, CTEXLI and investigational programs such as volixibat and brelovitug.
The company’s SEC record also covers capital-structure and transaction disclosures, including the completed Bluejay Therapeutics acquisition, related pro forma financial information and a PIPE financing. Proxy filings describe annual meeting matters, board elections, executive compensation and equity-plan governance, while registration details identify Mirum common stock as listed on the Nasdaq Global Market under MIRM.
Mirum Pharmaceuticals, Inc. (MIRM) reported that Chief Executive Officer Christopher Peetz exercised fully vested stock options for 30,000 shares of common stock on September 1, 2026 at an exercise price of $2.936 per share, receiving 30,000 shares of common stock. On the same date, he sold 8,312 shares at a weighted average price of $98.08 per share and 21,688 shares at a weighted average price of $98.91 per share under a Rule 10b5-1 trading plan adopted on March 2, 2026. Following the option exercise, he held 58,487 stock options directly and 187,500 shares of common stock indirectly through The Peetz Family Trust.
Mirum Pharmaceuticals, Inc. (MIRM) is the issuer in a Rule 144 notice covering proposed sales of its common stock for the account of officer Jolanda Marie Howe. The planned sale involves 658 shares of common stock through a broker, Morgan Stanley Smith Barney LLC Executive Financial Services, with a stated dollar amount of $65,800.00 as of September 2, 2026.
The shares to be sold are identified as restricted stock acquired from the issuer on January 23, 2026. The notice also lists prior sales by Jolanda Marie Howe over the preceding three months, including 40,000 shares for $4,000,000.00 on August 18, 2026 and several smaller transactions in June, July, and early August 2026.
Mirum Pharmaceuticals, Inc. (MIRM) received a Rule 144 notice from stockholder Christopher Peetz covering a planned sale of up to 30,000 shares of common stock, to be sold through Morgan Stanley Smith Barney LLC on or after 09/01/2026, following a stock option exercise. The notice also lists sales during the prior three months totaling 40,000 shares of Mirum common stock.
Mirum Pharmaceuticals, Inc. (MIRM) reported insider equity transactions by Jolanda Howe, its SVP, Global Controller. On 2026-08-18, Howe exercised 40,000 employee stock options at an exercise price of $6.27 per share, acquiring an equal number of common shares. On the same date, she sold 40,000 common shares at $100.00 per share in a transaction described as a sale in an open market or private transaction. The option grant was fully vested at the time of exercise, and the option position reported in this filing was reduced to zero.
Mirum Pharmaceuticals, Inc. (MIRM) reports that officer Jolanda Marie Howe has notified of a proposed sale of 40,000 common shares, to be sold for cash on 08/18/2026 through Morgan Stanley Smith Barney, with an aggregate market value of $4,000,000.00, following a stock option exercise. She also reported prior sales of 1,840, 2,721, and 2,594 shares of common stock in June, July, and August 2026, respectively.
Janus Henderson Group Ltd., a Jersey-organized asset management group, reports beneficial ownership in Mirum Pharmaceuticals, Inc. common stock. Through its various investment adviser subsidiaries managing client accounts referred to as Managed Portfolios, it may be deemed to beneficially own 5,909,184 shares of Mirum common stock, representing 9.7% of the class as of June 30, 2026. Janus Henderson has no sole voting or dispositive power over these shares but holds shared voting and shared dispositive power over all 5,909,184 shares. The Managed Portfolios, not Janus Henderson or its parent owners, have the right to receive all dividends and sale proceeds, and no single Managed Portfolio holds more than five percent of Mirum’s common stock.
Mirum Pharmaceuticals, Inc.'s Chief Financial Officer, Eric Bjerkholt, reported a sale of 6,001 shares of common stock on August 11, 2026 at a weighted average price of $99.90 per share, in a transaction described as a sale in the open market or a private transaction. The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on March 9, 2026. Following this transaction, Bjerkholt beneficially owns 36,355 shares of Mirum common stock, including 175 shares acquired on May 10, 2026 under the Employee Stock Purchase Plan.
Mirum Pharmaceuticals, Inc. CEO Christopher Peetz exercised an employee stock option for 20,000 shares of common stock at an exercise price of $2.936 per share and received 20,000 shares on August 10, 2026. On the same date he sold a total of 20,000 common shares in three tranches at weighted average prices of $98.51, $99.25, and $100.14 per share pursuant to a Rule 10b5-1 Plan. Following the option exercise, he reported 88,487 stock options remaining and an indirect holding of 187,500 shares held by The Peetz Family Trust.
MIRM insider Eric Bjerkh olt filed a notice to sell up to 6,001 shares of common stock through Morgan Stanley Smith Barney LLC’s Executive Financial Services, with an indicated aggregate market value of $599,509.50 on NASDAQ as of August 11, 2026. The notice references underlying awards of 3,334 and 2,667 restricted stock shares dated September 11, 2024 and January 23, 2025. It also lists prior sales during the past three months of 5,000 shares for $611,270.00 on July 6, 2026 and 5,000 shares for $469,073.00 on June 8, 2026.
Christopher Peetz filed a Form 144 indicating an intent to sell 20,000 shares of common stock of MIRM through Morgan Stanley Smith Barney LLC Executive Financial Services on or after 08/10/2026, in connection with a stock option exercise. The notice also reports prior sales over the past three months: 20,000 shares on 07/06/2026 for an aggregate of $2,445,434.00 and 30,000 shares on 06/01/2026 for an aggregate of $2,875,107.00.